Loading clinical trials...
Loading clinical trials...
A Phase I and Feasibility Study of Everolimus (RAD001) Plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions
Interventions
rituximab
cyclophosphamide
+4 more
Locations
1
United States
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
Start Date
March 1, 2012
Primary Completion Date
February 1, 2015
Completion Date
August 1, 2017
Last Updated
August 10, 2017
NCT05529069
NCT05139017
NCT06337318
NCT06263491
NCT07388563
NCT07350863
Lead Sponsor
Alliance for Clinical Trials in Oncology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions